Recent health developments include Eli Lilly's Alzheimer's treatment approval in China, a DOJ lawsuit against CVS for opioid ...

Minnesota Alzheimer's patients will be among the first to receive a new treatment through the drug Kisunla, which targets the ...

FOX 9 caught up with a Minnesota woman undergoing a new Alzheimer’s treatment which is showing promise in slowing cognitive ...

Kathy Ingebrand of Mahtomedi is one of the first people in the country to receive the infusion meant to slow down Alzheimer's disease by up to 35%.

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...

Eli Lilly and EVA Pharma have announced approval from the Egyptian Drug Authority for the human insulin glargine injection.

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt, ...